A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas

Download All
In this comprehensive online program, experts discuss how to select optimal therapies for patients with B-cell lymphomas. Get up to date with expert commentaries, an on-demand webcast and slides from a dynamic CCO symposium at ASH 2021, downloadable resources on 10 key agent classes, and an audio podcast.
Brad S. Kahl, MD
John P. Leonard, MD

ClinicalThought

Treatment options have grown increasingly complex for patients with follicular lymphoma. In this commentary, I share how I approach individualizing and sequencing therapy for patients with newly diagnosed and relapsed/refractory disease.

John P. Leonard, MD Released: November 1, 2021

How are you managing patients with mantle cell lymphoma? Read this commentary for my approach.

Brad S. Kahl, MD Released: November 12, 2021

Now that ibrutinib and zanubrutinib are both approved by the FDA in the relapsed/refractory setting for marginal zone lymphoma, where do we sequence and how do we choose between these BTK inhibitors? Read this commentary for my approach.

John P. Leonard, MD Released: November 2, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Atara Biotherapeutics, Inc.
Bayer HealthCare Pharmaceuticals Inc.
BeiGene, Ltd.
Epizyme
Genentech, a member of the Roche Group
Genmab US, Inc.
Incyte Corporation
Karyopharm Therapeutics
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue